查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1963836

放射性藥物市場－全球產業規模、佔有率、趨勢、機會和預測：按類型、來源、最終用戶、地區和競爭格局分類，2021-2031年

Radiopharmaceuticals Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Source, By End user, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球放射性藥物市場預計將從 2025 年的 61.2 億美元成長到 2031 年的 83.2 億美元，複合年成長率為 5.25%。

這些結合了放射性同位素和藥物的製劑在診斷影像檢查和標靶治療介入中都發揮著至關重要的作用。推動其成長的主要因素是全球慢性病（尤其是腫瘤和心血管疾病）發生率的上升，這些疾病需要高度精確的診斷工具。此外，全球人口老化也持續推高了對核子醫學的需求，因為老年人通常需要更頻繁的監測和介入。根據世界核能學會預測，到2025年，全球每年將進行超過5,000萬例核醫檢查，凸顯了這些產品在現代醫療保健體系中的關鍵作用。

市場概覽
預測期 2027-2031
市場規模：2025年 61.2億美元
市場規模：2031年 83.2億美元
複合年成長率：2026-2031年 5.25%
成長最快的細分市場 診斷用放射性藥物
最大的市場 北美洲

儘管市場成長迅速，但複雜的物流配送仍為分銷帶來了巨大挑戰。許多具有重要臨床意義的同位素會發生快速的放射性崩壞，因此供應鏈必須嚴格把控時間，即使運輸過程中出現輕微延誤也可能導致產品過期或報廢。由於同位素生產依賴於數量有限的核子反應爐，這種物流脆弱性進一步加劇，造成嚴重的供應不穩定，並限制了新興市場對這些關鍵治療方法的供應。

市場促進因素

標靶放射性核種療法的加速普及正在從根本上改變全球市場，推動產業重心從診斷影像轉向精準治療性介入。與傳統的體外放射線治療不同，這些全身性療法利用特定的生物標記將放射性物質直接輸送到癌細胞，在最大限度地提高療效的同時，最大限度地保護健康組織。核准藥物的強勁收入成長證明了該治療方法的商業性潛力。根據BioSpace公司2024年10月發布的公告，其前列腺癌藥物Pluvicto僅在第三季的銷售額就達到了3.86億美元，年增50%。這項應用凸顯了治療診斷學的臨床價值，並鞏固了腫瘤學領域向個人化核醫學的轉變。

同時，政府撥款和私人投資的增加正在緩解核醫領域傳統的供應鏈瓶頸，並促進創新。領先的製藥公司正積極收購專業的生物技術公司，以確保自身放射性同位素的生產能力並拓展其腫瘤產品組合。例如，根據《製藥技術》雜誌2024年2月報道，百時美施貴寶以約41億美元收購了RaiseBio，從而獲得了其基於錒的放射性藥物平台。這種策略整合的趨勢進一步增強了該產業的長期財務穩定性。Astra Zeneca在2024年宣布，該公司已完成對Fusion Pharmaceuticals的收購，交易金額約24億美元，這加強了該產業擴大下一代放射性標記化合物規模的努力。

市場挑戰

全球放射性藥物市場面臨許多成長障礙，主要源自於產品分銷物流的複雜性和供應鏈固有的不穩定性。由於放射性藥物含有半衰期短的同位素，崩壞極快，無法儲存，因此需要嚴格同步的「準時制」配送模式。這項限制意味著，即使運輸過程中出現輕微延誤，也可能導致產品過期和經濟損失，直接減少可治療的患者數量，並限制收入潛力。因此，物流基礎設施落後地區的醫療機構往往難以獲得這些關鍵的診斷和治療藥物，從而有效地限制了市場的地域覆蓋範圍。

市場對少數核子反應爐的高度依賴進一步加劇了這種脆弱性，這意味著單一反應器的運作故障可能引發全球危機。據歐洲核醫學協會稱，2024年關鍵生產核子反應爐運作的意外延遲導致多個地區關鍵醫用同位素短缺，短缺率從50%到100%不等。如此嚴重的供應中斷迫使醫院暫停或推遲手術，削弱了人們對核子醫學的信心，並阻礙了整個產業的發展。

市場趨勢

新型放射性同位素的商業化正在拓展診斷能力，使診斷手段從鎵-68等傳統示蹤劑轉向銅-64等新一代示蹤劑。銅-64具有更優異的成像性能和物流優勢。這些新型同位素半衰期長，可實現集中生產和廣域分銷，有效緩解了短壽命示踪劑帶來的供應鏈瓶頸。 Clarity Pharmaceuticals公司在2025年1月預測，光是在美國，第一代PSMA PET影像的市場規模就將達到約20億美元，凸顯了這些先進診斷技術的經濟潛力。該公司認為，臨床排班柔軟性可能會使銅基示踪劑獲得顯著的市場佔有率。

同時，纖維母細胞活化蛋白 (FAP) 抑制劑的研發正在腫瘤學領域建立一種新的範式，其標靶不再是惡性細胞本身，而是腫瘤微環境。這種作用機制克服了抗原特異性放射性配體的限制（後者往往僅限於單一適應症），從而實現了對多種上皮腫瘤的泛癌成像和治療。為了支持業界擴大這種前景廣闊的治療方法的規模，Contract Pharma 於 2025 年 5 月報道稱，Ratio Therapeutics 已宣布達成協議，將在猶他州建造一座佔地 65,000 平方英尺的工廠，專門用於其 FAP 靶向產品線的垂直整合和商業化生產。這項基礎設施投資凸顯了 FAP 抑制劑正迅速從實驗研究階段過渡到可規模化的臨床應用。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球放射性藥物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（診斷用放射性藥物、治療放射性藥物）
    • 供應來源（核子反應爐、迴旋加速器）
    • 依最終使用者（醫院/診所、診斷影像中心、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美放射性藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲放射性藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區放射性藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲放射性藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲放射性藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球放射性藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • PharmaLogic Holdings LLC
  • Jubilant Radiopharma
  • China Isotope & Radiation Corporation
  • Siemens Healthineers AG
  • SHINE Technologies, LLC
  • Ion Beam Applications SA
  • Global Medical Solutions
  • BWX Technologies. Inc
  • CoquI Radio Pharmaceuticals Corp.
  • Evergreen Theragnostics, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23964

The Global Radiopharmaceuticals Market is projected to expand from USD 6.12 billion in 2025 to USD 8.32 billion by 2031, reflecting a compound annual growth rate of 5.25%. These medicinal formulations, which combine radioactive isotopes with pharmaceutical agents, are essential for both diagnostic imaging and targeted therapeutic interventions. Growth is largely driven by the rising global incidence of chronic diseases, particularly oncology and cardiovascular disorders, which demand high-precision diagnostic tools. Additionally, the aging global demographics sustain demand for nuclear medicine, as elderly populations typically require more frequent monitoring and intervention. According to the World Nuclear Association, more than 50 million nuclear medicine procedures are conducted annually worldwide as of 2025, highlighting the vital role these products play in modern healthcare systems.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.12 Billion
Market Size 2031USD 8.32 Billion
CAGR 2026-20315.25%
Fastest Growing SegmentDiagnostic Radiopharmaceuticals
Largest MarketNorth America

Despite this growth, the market encounters significant hurdles related to the complex logistics needed for distribution. The rapid radioactive decay of many clinically vital isotopes necessitates a strictly timed supply chain, where even minor transportation delays can lead to product expiration and wastage. This logistical fragility is intensified by a dependence on a limited number of nuclear reactors for isotope production, creating severe supply vulnerabilities and restricting the availability of these essential treatments in emerging markets.

Market Driver

The accelerating adoption of targeted radionuclide therapy is fundamentally transforming the global market, moving the industry's focus from diagnostic imaging toward precision therapeutic interventions. Unlike conventional external beam radiation, these systemic treatments employ specific biomarkers to deliver radioactive payloads directly to cancer cells, maximizing efficacy while sparing healthy tissue. The commercial potential of this modality is demonstrated by the robust revenue growth of approved agents. According to BioSpace in October 2024, the prostate cancer therapy Pluvicto generated $386 million in sales during the third quarter alone, marking a 50% year-over-year increase. This adoption underscores the clinical value of theranostics and confirms the shift toward personalized nuclear medicine in oncology.

Concurrently, increased government funding and private investment in nuclear medicine are addressing historical supply chain limitations and driving innovation. Major pharmaceutical companies are actively acquiring specialized biotechnology firms to secure proprietary radioisotope manufacturing capabilities and broaden their oncology portfolios. For instance, Pharmaceutical Technology reported in February 2024 that Bristol Myers Squibb acquired RayzeBio for approximately $4.1 billion to access its actinium-based radiopharmaceutical platform. This trend of strategic consolidation is further solidifying the sector's long-term financial stability; as noted by AstraZeneca in 2024, the company completed its acquisition of Fusion Pharmaceuticals for roughly $2.4 billion, reinforcing the industry's dedication to scaling next-generation radioconjugates.

Market Challenge

The Global Radiopharmaceuticals Market encounters a significant barrier to growth stemming from the complex logistics of product distribution and the inherent instability of its supply chain. Because radiopharmaceuticals contain isotopes with short half-lives, they decay quickly and cannot be stockpiled, requiring a strictly synchronized "just-in-time" delivery model. This constraint implies that even minor delays in transportation inevitably result in product expiration and financial loss, directly reducing the number of patients treated and curbing revenue potential. As a result, healthcare facilities in regions with underdeveloped logistical infrastructure often struggle to access these critical diagnostics and therapies, effectively limiting the market's geographical reach.

This fragility is further compounded by the market's heavy dependence on a small number of nuclear reactors, where a single operational disruption can precipitate a global crisis. According to Nuclear Medicine Europe, in 2024, unexpected delays in the restart of a major production reactor led to supply shortages of critical medical isotopes ranging from 50% to 100% across various regions. Such severe interruptions compel hospitals to cancel or postpone procedures, undermining confidence in nuclear medicine and hindering the overall progress of the industry.

Market Trends

The commercialization of novel radioisotopes is expanding diagnostic capabilities, shifting beyond legacy agents like Gallium-68 to next-generation options such as Copper-64, which offer superior imaging characteristics and logistical benefits. These novel isotopes possess extended half-lives that support centralized manufacturing and wider geographic distribution, effectively mitigating the supply chain constraints associated with shorter-lived tracers. Highlighting the economic potential of these advanced diagnostics, Clarity Pharmaceuticals noted in January 2025 that the current market for first-generation diagnostic PSMA PET imaging is valued at approximately $2 billion in the U.S. alone, positioning copper-based alternatives to capture significant market share by enhancing clinical scheduling flexibility.

Simultaneously, the development of Fibroblast Activation Protein (FAP) inhibitors is establishing a new paradigm in oncology by targeting the tumor microenvironment rather than malignant cells directly. This mechanism enables pan-cancer imaging and treatment of various epithelial tumors, addressing the limitations of antigen-specific radioligands that are often restricted to single indications. Validating the industry's commitment to scaling this promising modality, Contract Pharma reported in May 2025 that Ratio Therapeutics announced an agreement to construct a 65,000-square-foot facility in Utah dedicated to the vertical integration and commercial production of its FAP-targeted pipeline. This investment in infrastructure underscores the rapid transition of FAP inhibitors from experimental research to scalable clinical solutions.

Key Market Players

  • PharmaLogic Holdings LLC
  • Jubilant Radiopharma
  • China Isotope & Radiation Corporation
  • Siemens Healthineers AG
  • SHINE Technologies, LLC
  • Ion Beam Applications SA
  • Global Medical Solutions
  • BWX Technologies. Inc
  • CoquI Radio Pharmaceuticals Corp.
  • Evergreen Theragnostics, Inc.

Report Scope

In this report, the Global Radiopharmaceuticals Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Radiopharmaceuticals Market, By Type

  • Diagnostic Radiopharmaceuticals
  • Therapeutic Radiopharmaceuticals

Radiopharmaceuticals Market, By Source

  • Nuclear Reactors
  • Cyclotrons

Radiopharmaceuticals Market, By End user

  • Hospitals & Clinics
  • Diagnostics imaging centre
  • Others

Radiopharmaceuticals Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Radiopharmaceuticals Market.

Available Customizations:

Global Radiopharmaceuticals Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Radiopharmaceuticals Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals)
    • 5.2.2. By Source (Nuclear Reactors, Cyclotrons)
    • 5.2.3. By End user (Hospitals & Clinics, Diagnostics imaging centre, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Radiopharmaceuticals Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Source
    • 6.2.3. By End user
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Radiopharmaceuticals Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Source
        • 6.3.1.2.3. By End user
    • 6.3.2. Canada Radiopharmaceuticals Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Source
        • 6.3.2.2.3. By End user
    • 6.3.3. Mexico Radiopharmaceuticals Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Source
        • 6.3.3.2.3. By End user

7. Europe Radiopharmaceuticals Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Source
    • 7.2.3. By End user
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Radiopharmaceuticals Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Source
        • 7.3.1.2.3. By End user
    • 7.3.2. France Radiopharmaceuticals Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Source
        • 7.3.2.2.3. By End user
    • 7.3.3. United Kingdom Radiopharmaceuticals Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Source
        • 7.3.3.2.3. By End user
    • 7.3.4. Italy Radiopharmaceuticals Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Source
        • 7.3.4.2.3. By End user
    • 7.3.5. Spain Radiopharmaceuticals Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Source
        • 7.3.5.2.3. By End user

8. Asia Pacific Radiopharmaceuticals Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Source
    • 8.2.3. By End user
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Radiopharmaceuticals Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Source
        • 8.3.1.2.3. By End user
    • 8.3.2. India Radiopharmaceuticals Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Source
        • 8.3.2.2.3. By End user
    • 8.3.3. Japan Radiopharmaceuticals Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Source
        • 8.3.3.2.3. By End user
    • 8.3.4. South Korea Radiopharmaceuticals Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Source
        • 8.3.4.2.3. By End user
    • 8.3.5. Australia Radiopharmaceuticals Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Source
        • 8.3.5.2.3. By End user

9. Middle East & Africa Radiopharmaceuticals Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Source
    • 9.2.3. By End user
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Radiopharmaceuticals Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Source
        • 9.3.1.2.3. By End user
    • 9.3.2. UAE Radiopharmaceuticals Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Source
        • 9.3.2.2.3. By End user
    • 9.3.3. South Africa Radiopharmaceuticals Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Source
        • 9.3.3.2.3. By End user

10. South America Radiopharmaceuticals Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Source
    • 10.2.3. By End user
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Radiopharmaceuticals Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Source
        • 10.3.1.2.3. By End user
    • 10.3.2. Colombia Radiopharmaceuticals Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Source
        • 10.3.2.2.3. By End user
    • 10.3.3. Argentina Radiopharmaceuticals Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Source
        • 10.3.3.2.3. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Radiopharmaceuticals Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. PharmaLogic Holdings LLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Jubilant Radiopharma
  • 15.3. China Isotope & Radiation Corporation
  • 15.4. Siemens Healthineers AG
  • 15.5. SHINE Technologies, LLC
  • 15.6. Ion Beam Applications SA
  • 15.7. Global Medical Solutions
  • 15.8. BWX Technologies. Inc
  • 15.9. CoquI Radio Pharmaceuticals Corp.
  • 15.10. Evergreen Theragnostics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer